Catalyst Wire Dossier Catalyst Wire Dossier

Aes-103

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Aes-103, covering 2014-10-24 to 2017-03-24. Get the full timeline:

Most recent: Clinical Trial Update: Evaluation of Different Dose Regimens of Aes-103 Given for 28 Days to Subjects With Stable Sickle Cell Disease [Phase 2]

See pricing